Hints and tips:
Related Special Reports
...“I watch the development people working on solid-state almost every month, so I know all the progress, and somehow we still have these showstoppers.”...
...Roughly a quarter of the funding comes via an equity investment, with the remainder composed of research grants and commitments for joint business development that will not dilute shareholders, said people...
...David Moore, vice-president for corporate development, added that the company would focus on acquisitions in diabetes and obesity, ideally in the early stage of development....
...The Development Bank of Japan is investing in 4Bio, which funds companies in the UK and Europe, alongside the Japanese pharma group Kyowa Kirin, and US healthcare provider, Children’s Minnesota. 4Bio aims...
...Dementia Mission and chief executive of Alzheimer’s Research UK....
...Since the third quarter of 2023 when it had 82 new drugs in development, the company has jettisoned 16 drugs and added 12 others, including the weight-loss drug it gained through its $3.1bn acquisition of...
...Developing new antibiotics is often unattractive for pharmaceutical companies, as research and development costs are high but their use is designed to be limited to reduce the risk of the product driving...
...The forced separation of research and trading, which required investors to pay separately for analysts’ musings, was clearly well-intentioned and sought to avoid conflicts of interest. Fine....
...Specification: Cognition and Development Click the link below to read the and then answer the questions: US seeks up to 50-year sentence for FTX founder Sam Bankman-Fried According to his lawyers quoted...
...Caroline Copeland, senior lecturer at King’s College London and the report’s senior author, said the research showed xylazine had “penetrated the UK’s illicit drug market”....
...But as the Duke of Albany warns King Lear, “Striving to better, oft we mar what’s well.” By making the cost explicit to fund managers, the unbundling rules prompted them to slash research budgets....
...The research charity noted there had been improvements in diagnosing and treating the disease in the years since the latest trial, conducted by the universities of Bristol, Oxford and Cambridge, began....
...The results from the research, which involved 156 people, were a “major breakthrough”, said Olivier Rascol, a Toulouse University Hospital professor and a co-author of the research with Prof Wassilios Meissner...
...Hello and welcome to the working week. The attempt to find a solution to the Israel-Gaza conflict comes to Washington on Monday with President Joe Biden playing host to King Abdullah of Jordan....
...According to a European Commission analysis of the world’s 2,500 highest spending companies in research and development published in 2023, 12 per cent of leading companies investing in health research are...
...A dearth of career scientists and public funding risks undermining efforts to use technological breakthroughs to tackle the biggest health threats, the head of a leading international research organisation...
...Martin Holst Lange, head of development at Novo Nordisk, said that Cardior’s drug had the “potential to become a first-in-class therapy designed to halt or partially reverse the course of disease for people...
...Thomson is a professor of experimental particle physics at the University of Cambridge and executive chair of the Science and Technology Facilities Council, a UK research organisation....
...“The development of models that can better replicate human diseases and accurately predict human responses promises to improve the outcomes of drug-development programmes,” said Silvia Velasco, an associate...
...Jodie Keane Senior Research Fellow ODI (Formerly Overseas Development Institute), London SE1, UK...
...senior author of the research....
...Susan Galbraith, executive vice-president of oncology research and development at AstraZeneca, said there was an “opportunity to improve” on existing drugs in the area and that the Fusion acquisition would...
...The UK government said in a statement: “Research and the life sciences are crucial in the fight against cancer, which is why we invest £1bn per year through the National Institute for Health and Care Research...
...Dean Li, president of Merck’s research laboratories, praised the UK’s scientific talent and expertise, hoping that the investment in King’s Cross will help researchers at MSD, known as Merck in the US, work...
...The reliance on animal testing brings further risks to the human subjects of clinical trials, and to the drug development process as a whole, Quantiphi argued....
International Edition